If a TF can bind specific genomic regions that lead to stable overexpression of a set of genes that give cells a selective advantage in the context of prostate cancer development, then this should be reflected in the enrichments regardless of the cell line or conditions in which the ChIP-seq study to profile the TF possible binding sites was performed. This evidence concerns the gene TF and prostate cancer.